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Abstract: Introduction: The aim of this study was to describe breast ductal cancer in situ (DCIS) 
incidence trends in women in the Girona province during a period of 25 years. The influence of age, use 
of mammography and implementation of the breast cancer screening programs was explored. 
Incidence of subsequent invasive breast cancers (IBC) and DCIS treatment was also considered. 
Materials and Methods: Cases diagnosed with primary pure DCIS (n=416) during 1983-2007 were 
extracted from the population-based Girona Cancer Registry. The estimated annual percent change 
was estimated using joinpoint analysis.                    
Results: DCIS incidence showed a sharp rise until 1998, followed by a less marked upward trend. 
Among women aged 50-69 the increase was particularly important between 1992 and in 1996, 
reflecting the spread in mammography use.  
Conclusion: The upward trend of DCIS was mainly related to an increase in mammography use either 
opportunistic or as a result of screening implementation.  
 
 
 
 
 
 1 
Rapid increase in incidence of breast ductal cancer in situ in Girona, 
Spain 1983-2007 
 
 
Puig Vives M
1,2
, Pollan M
3,4
, Rue M
5
, Osca G
1,2
, Izquierdo A
1,6
, Marcos-Gragera R
1, 4
  
 
1 
Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan. 
Department of Health. Autonomous Government of Catalonia. Catalan Institute of 
Oncology, Girona, Spain 
2 
University of Girona, Girona, Spain 
3
 Cancer Epidemiology Unit, National Center of Epidemiology, Instituto de Salud 
Carlos III, Madrid, Spain  
4
 CIBER Epidemiology and Public Health, Spain  
5
 Basic Medical Sciences Department, Biomedical Research Institute of Lleida 
(IRBLLEIDA)-University of Lleida, Lleida, Spain 
6
 Medical Oncology Unit, Catalan Institute of Oncology, University Hospital Dr. Josep 
Trueta, Girona, Spain. 
 
 
 
Introduction 
Invasive female breast cancer (IBC) is the most frequent tumor in women in Spain. In 
the 2000-2004 period, IBC incidence was 83.8 per 100,000 women-year and within 
Spain, Girona had the highest rate (95.5 per 100,000 women-year) (1). It is well known 
that during the recent decades ductal carcinoma in situ (DCIS) incidence has increased 
*Manuscript
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in several countries (2-7). This rising has been associated with the implementation of 
breast cancer screening programs, but screening does not completely explain the upward 
trend and other factors might also play a role (2;6). DCIS refers to breast epithelial cells 
that have become “cancerous” but still reside in the milk ducts. It is thought that most 
IBC evolve through nonobligatory stages, referred to as hyperplasia, atypical 
hyperplasia and in situ carcinoma. However, the possibility that both DCIS and IBC 
may develop in parallel it has been also suggested (8;9). DCIS may be presented as a 
palpable or non-palpable nodule. Screening mammography has increased the detection 
of non-palpable breast cancer and pre-invasive lesions. Currently the most common 
DCIS clinical presentation are the impalpable lesions (10;11).  
 
It has been previous reported that risk factors associated with DCIS are similar to those 
associated with IBC, although some are differently related to various types of DCIS 
(comedo and non-comedo) (12;13). Women diagnosed with DCIS have an increased 
risk of developing IBC in the ipsi- or contralateral breast compared with women in the 
general population. However, the progression into IBC is unknown and it is not possible 
to identify which DCIS will progress to IBC (6;14). A recent study shows that less than 
10% of DCIS patients treated by excisions alone developed IBC after 5 years; while 
another study demonstrates that about 15% of patients who are initially diagnosed with 
DCIS on core needle biopsy have IBC identified in the excision or mastectomy 
specimen. It has been estimated that 14-50% of DCIS lesions would progress to IBC if 
left untreated. Several studies showed that mortality from breast cancer is low among 
women diagnosed with DCIS (13-16). 
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The rising DCIS incidence presents a clinical problem because there is not an effective 
protocol to distinguishing which women will or will not develop IBC and so, to what 
extent treatment may benefit a particular patient. Hence, the therapeutic goal is to 
reduce risk of recurrent disease, particularly IBC. There is some controversy as to 
whether or not total mastectomy or a lumpectomy with radiation may constitute 
overtreatment, given that the majority of DCIS patients will not develop invasive 
disease (5;14;17). Current clinical recommendations indicate that DCIS patients may be 
treated with lesion excision and radiotherapy and in some cases (multifocality) 
mastectomy or lumpectomy and radiotherapy should be regarded. Tamoxifen should be 
considered in patients with positive estrogen receptor tumours (18;19). 
 
Population-based data on incidence trends of DCIS from Spain are not available. To 
understand the possible extent of overdiagnosis and overtreatment of DCIS, it is 
important to have information about treatment and incidence of the disease over time. 
The aim of this study was to describe DCIS incidence trends in women resident in the 
Girona province during the period from 1983 to 2007, considering the implementation 
of the population-based mammography screening program. Given the differential 
impact of breast cancer screening programs on age-specific incidence rates, we also 
analyzed DCIS trends incidence separately for women younger than 50 years, those 
aged 50-69 years, and those 70 years or older. Treatment of DCIS diagnosed from 2000 
to 2007 was reported and finally, the incidence of IBC subsequent to DCIS was also 
described.  
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Materials and Methods 
Data 
Data were extracted from the population-based Girona Cancer Registry (GCR). The 
GCR is located in the Northern East of Catalonia, in Spain, covering a population of 
339,660 women at the 2007 census. It represents a 9.35% of the Catalan population. 
Catalan data of female population used for the statistical analyzes were obtained from 
the Institut d’Estadística de Catalunya (20). The GCR collects invasive and in situ 
breast tumors since 1980 and case registration is performed according to the European 
Network of Cancer Registries (ENCR) recommendations (21;22).  
 
We restricted our analysis to women diagnosed of DCIS during the period from 1983 to 
2007. The following ICD-10 classification codes were used; D050-D059 (23). A total of 
416 cases were included in the study. Cases diagnosed with lobular in situ carcinoma 
(n=17), or intraductal carcinoma and lobular in situ (n=1), or intracystic carcinoma (n= 
2) were excluded. Data of the first tumor in women with bilateral DCIS was recorded. 
Each woman with DCIS has been followed up to December 31
th
 2007 to evaluate the 
occurrence of a subsequent IBC in the ipsi- or contralateral breast. However, in order to 
have a minimum follow-up of 1 year, women diagnosed with DCIS in 2007 (n=41) 
were not included in this analysis. Surgical treatment was recorded in women diagnosed 
with DCIS during the period 2000 to 2007, and classified into the following groups: 
Conservative surgery alone, including lumpectomy, excision and quadrantectomy; 
conservative surgery plus radiotherapy; mastectomy, including modified radical 
mastectomy and simple mastectomy and non-surgery. Molecular and hormonal 
treatments were not reported. 
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In Spain there is a National Health System (NHS), financed mainly by taxes, which 
provides universal health coverage, including early detection of breast cancer. In the 
Girona province, the Breast Cancer Screening Program (Programa de Detecció Precoç 
del Càncer de Mama, PDPCM) gradually started in the different hospitals during the 
period 1999 to 2002, providing biennial mammography screening test to women from 
50 to 69 years old. PDPCM coverage of the whole Girona province in 2007 was 75.29% 
with a participation of 63.15%. The Catalan Health Surveys in 1994, 2002 and 2006 
describe the percentage of women older than 20 years undergoing mammography 
periodically in Girona (24-26).  
  
Analyses 
Mean age (SD) at diagnosis of DCIS and IBC (codes C500-C509 of the ICD-10) (23) 
were calculated and compared using t test. DCIS incidence rates were estimated for 
each 5-year period (1983-1987, 1988-1992, 1993-1997, 1998-2002 and 2003-2007) as 
the crude rate (CR), the age-standardized to the World standard population rate (ASRW), 
and the age-specific rate for 5-year aged (25-29, …, 80-84, >85). ASRW was also 
calculated according to three age groups (<50, 50-69, >69). These age cut points were 
chosen because PDPCM targets women aged 50-69 years. Epidat software (27) was 
used to compute CR and ASRW with the 95% confidence interval (95% CI) by using the 
direct method. Joinpoint statistical software was used to quantify the evolution of DCIS 
incidence, as the Estimated Annual Percent Change (EAPC), and to evaluate changes in 
trends along time in the three broad age groups (28). Median (range) months between 
DCIS and IBC were calculated for tumors developed in the ipsilateral or in the 
contralateral breast.  
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Results 
A total of 416 incident cases of DCIS were identified by GCR from 1983 to 2007. Mean 
age (SD) at diagnosis was 55.82 (12.32) years, ranging from 26 to 89 years. Mean age 
(SD) at diagnosis of the IBC in the same period was 61.41 (14.83) years, ranging from 
21 to 103 years. If only incident cases diagnosed during the screening period (2002-
2007 years) were considered, mean age was 55.47 (11.79) years for DCIS and 61.70 
(15.05) years for IBC. Differences between mean ages of invasive and in situ cancers 
were statistically significant using t test (P value < 0.001). DCIS accounted for 6.85% 
of breast carcinomas diagnosed between 1983 and 2007, excluding lobular and 
intracystic invasive carcinomas.   
 
Table 1 show the incidence expressed as CR and ASRW per 100,000 women-year. 
Overall, ASRW increased during the studied period, from 1.01 in 1983-1987 to 8.24 in 
2003-2007. In general, during the 1980s and the beginning of the 1990s incidence rates 
remained low and began to increase during the 1990s.   
 
As Figure 1 depicts, from 1983 to 1998 DCIS incidence increased rapidly. In 1998 the 
joinpoint model indicated a statistically significant change in trend (95% CI: 1994 to 
2001; P value for the existence of a change point < 0.05). Incidence rates raised by 
18.31% (95% CI: 11.86% to 25.14%) per year until 1998 and thereafter the increment 
was 2.95% and no longer statistically significant (95% CI: -2.74% to 8.98%).  
DCIS incidence changed over time according to age (Figure 2). In women under 50 
years, DCIS steadily increased at a statistically significant EAPC of 10.31% (95% CI: 
7.39% to 13.30%) over the entire period. Among women aged 50-69 years, two 
statistically significant change points were observed in 1992 (95% CI: 1985 to 1994; P 
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value for the existence of a change point < 0.05) and in 1996 (95% CI: 1994 to 1998; P 
value for the existence of a change point < 0.05). In this age group, DCIS incidence 
increased at a non-statistically significant annual rate of 9.06% (95% CI: -7.72% to 
28.89%) until 1992 and then sharply jumped at an annual rate of 59.42% (95% CI: -
0.30% to 154.91%) until 1996. From 1996 to 2007, DCIS incidence seemed to level off 
(EAPC= 2.03%; 95% CI: -1.79% to 6.01%). Finally, among women aged 70 years or 
older, no change point was observed and the none statistically significant annual 
increase in incidence was 3.61% (95% CI=-1.18% to 8.64%). During the fully 
implemented PDPCM screening period (2002-2007 years), 54.9% of all DCIS in 
women 50-69 years old were screen-detected (n=62), 6.2% were interval cancers (n=7) 
and 39.0% were DCIS diagnosed outside the program (n=44). 
Age-specific rates for the whole period are shown in Figure 3. DCIS increased with age 
in women aged 25-49 years, peaked at 50-54 years and decreased in those older than 65.  
Information regarding the type of surgery was obtained in 75.8% of all DCIS diagnosed 
between 2000 and 2007 (191 out of 252). Half of them were treated with conservative 
surgery plus radiotherapy (95 in 191), but a 35.8% of these women were 
mastectomized. A low percentage (8.4%) was treated with conservative surgery alone 
and only 2 cases (1%) were not operated. 
About 21% of women diagnosed with DCIS until 2006 (n=377) also developed an 
invasive cancer (n=81) before or/and after DCIS diagnosis. Invasive second cancers 
were localized in breast, colon, cervix and corpus uteri and thyroid gland. Out of all 
women included in the study until 2006, 4.0% (n=15) developed an IBC subsequent 
DCIS. One woman developed bilateral IBC after DCIS. Of all IBC, 50.0% (n=8) 
occurred in the contralateral breast and 50.0% (n=8) were diagnosed in the ipsilateral 
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breast. For the contralateral IBC the median of time between DCIS diagnosis and IBC 
diagnosis was 32.5 month (range, 4 to 124 month), and for ipsilateral was 81.5 month 
(range, 20 to 211 month). 
 
Discussion 
Our results show that DCIS incidence in the Girona province markedly increased from 
1983 to the end of 1990s remaining stable afterwards. During the period from 1980 to 
1999 in Girona the incidence of IBC increased 2.7% per year (29). Since the PDPCM 
started in the Girona province in 1999, DCIS incidence had remained stable considering 
all age groups together. PDPCM was not fully implemented in the whole province until 
2002 but DCIS incidence trend markedly changed in 1998. Before PDPCM 
implementation, women used the mammography as a spontaneous preventive practice, 
in the public and private health care sectors, as it occurred in other countries (2). 
Mammography in Catalonia started during 1980s but spread during 1990s. In 1980 only 
10 mammography equipments were available, while in 2000 there were already 134 
(29). The Catalan Health Survey describes that rates of screening mammography in 
Girona were lower in 1994 (25.18%) than in 2002 (38.8%) and in 2006 (42.9%) (24-
26;30). The observed increment was concurrent with the increased DCIS detection. 
During the screening period incidence remained high and stable; about half of the 
women aged 50-69 years were diagnosed by opportunistic mammography and the other 
half by the screening program. During the entire period studied DCIS incidence trends 
reflected the mammography use. 
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Part of the diagnosed DCIS included in the study were asymptomatic and would be 
undetected if screening had not been performed, given that some DCIS may lack 
progressive potential. From this point of view screening would be considered as causing 
overdiagnosis (14;31). Probably, DCIS diagnosed before mammography spread were 
symptomatic, whereas currently both asymptomatic and symptomatic DCIS are being 
diagnosed. This is possible because of the widespread use of mammography and the 
awareness of its role to prevent the disease among the general population and among 
medical professionals. 
 
Coinciding with a previous study, the most frequent second cancer among women with 
DCIS is IBC, followed by colon and corpus uteri invasive cancer, among others (32). It 
has to be considered the possibility that in some cases the DCIS detected would be 
already invasive, but not diagnosed as such. Women with DCIS were almost all treated 
and a 35.8% were mastectomized, resulting in a possible overtreatment. However, DCIS 
treatment was necessary to obtain a low percentage of subsequent IBC if we considered 
the estimation that 14-50% of DCIS would progress to IBC if left untreated (16). 
Although screening would cause overdiagnosis and overtreatment, a non-negligible 
proportion of DCIS progress into IBC.  
 
We observed that changes in DCIS incidence highly differed by age groups. Among 
women aged 50-69 years, there was an abrupt climb of DCIS incidence in the mid 
1990s, whereas among women aged 70 or older and women aged 49 or younger 
incidence has been gradually increasing. In Spain, IBC in young women is still rising, 
while in many other developed countries it has stabilized (1;33-35). Our results indicate 
that DCIS incidence in young women appeared to increase steadily across the entire 
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study period and it has not completely reached stability, as well as the invasive disease. 
Although these women are not included in the PDPCM, the widespread use of 
mammography might nevertheless influenced diagnosis in such women. It was previous 
reported that there has been an increase in mammography use over time in women in 
their late 30s or early 40s (31). Taking into account that some risk factors for DCIS are 
similar to those for IBC, the observed steadily rise of DCIS in young women may be 
also due to the lifestyle changes experienced by Spanish women in the recent decades. 
In Spain, fertility had sharply declined, the mean age at menarche had decreased more 
than in other European countries and the mean age at first child’s birth had increased 
(6;34). On the other hand, DCIS among women aged 70 years or older also showed an 
upward trend during all the study period, but it was not statistically significant. A 
previous study showed a gradual stabilization of IBC incidence since 1995 in this age 
group in Spain (1). Regarding invasive cancers, diagnostic anticipation and treatment of 
preinvasive lesions could have contributed to reduce incidence. However, the increase 
in DCIS observed among women older than 69, may be also partly explained by 
opportunistic mammography after leaving the screening program.    
 
Women aged 50-69 years, was the age group that in 2002 and 2006 reported the highest 
use of periodic mammograms in the Catalan Health Surveys, followed by the 40-49 age 
group (31). Unlike IBC, age specific rates of DCIS increased up to 50-54 years and then 
decreased. This may reflect the mammography use pattern in Girona, which included 
women from 40 to 75 years. Furthermore, DCIS rates in women 45 to 49 years old 
appeared to be similar to those observed in the screening age interval.  
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Results also show that the mean age of women diagnosed with DCIS was significantly 
lower than the mean age of women diagnosed with IBC. This may be explained by an 
advanced diagnosis of DCIS respect to IBC due to mammography implementation. A 
previous study reported that in the U.S.A., between 1975 and 2003, women diagnosed 
with DCIS were also younger than women diagnosed with IBC (36).  
 
Some limitations must to be considered when interpreting our findings. Firstly, PDPCM 
was progressively implemented in the population adscribed to the different Screening 
Radiological Units during 1999-2002. Furthermore, they have different coverage (65.4-
87.01% in 2007) and participation rates (47.59-77.96% in 2007). These differences are 
likely to have influenced breast cancer incidence by increasing heterogeneity within the 
Girona province. Secondly, it must be taken into account diversity of data used, as they 
are provided by different hospitals, oncologists and pathologists. Thirdly, improved 
detection methods may have increased incidence during the recent years (digital 
mammography). In this regard it should be noted that digital mammography was 
introduced in Girona in 2005.  
 
Conclusions 
The described upward trend of DCIS in the Girona province in 1983-2007 was mainly 
related to the opportunistic mammography spread and also the PDPCM implementation. 
This increase was more pronounced in women under 70 years, particularly women aged 
50-69 years. Moreover, improved diagnostics and breast awareness resulting from the 
implementation of screening are also increasing DCIS trends. More research is needed 
in order to improve breast DCIS diagnostic methods and treatment.  
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Table 1. Incidence of breast ductal carcinoma in situ in Girona (Spain), 1983-2007.  
 
 
 
 
 
 
 
Incidence rated expressed by 100,000 women-year. N: incident cases, CR: crude rate, ASRW: standardized incidence rate, 95% CI: 95% of 
confidence interval 
 
 
 
 
 
Incidence 
 
 
1983-1987 1988-1992 1993-1997 1998-2002 2003-2007 
 Total 
 
1983 - 2007 
N 
 
15 20 72 132 177 
 
416 
CR 
 
1.33 1.63 5.52 9.61 11.20 
 
6.29 
ASRW   
(95% CI) 
 1.01 
(0.47-1.55) 
1.23 
 (0.64-1.82) 
4.41 
(3.36-5.47) 
7.17 
(5.89-8.44) 
8.24  
(6.99-9.49) 
 4.78 
(4.30-5.26) 
Table(s)
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Figure 1. Trends in age-adjusted incidence of breast ductal carcinoma in situ in Girona (Spain), 1983-2007. The observed rates (dotte  lines) were obtained by using ge-adjusted i cidence fo  each year, and the estimated temporal trends
The estimated temporal trends were obtained from fitting a joinpoint model in women aged < 50, 50-69 and >70 years (see 
“Materials and Methods”).
0
5
10
15
20
25
30
35
1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007
A
g
e-
sp
ec
if
ic
 r
at
e 
p
er
 1
0
0
.0
0
0
 w
o
m
en
-y
ea
r
Year of diagnosis
< 50 years 50-69 years > 69 years
EAPC1983-1992: 9.06% (-7.72%; 28.89%)
EAPC1993-1996: 59.42% (-0.30%; 154.91%)
EAPC1997-2007: 2.03% (-1.79%; 6.01%)
EAPC1983-2007: 3.61% (-1.18%; 8.64%)
EAPC1983-2007: 10.31% (7.39%; 13.30%)
Figure 2. Trends in age-specific breast ductal carcinoma in situ rates from 1983 to 2007 among women aged <50, 50-69 and >70 
years in Girona (Spain)
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Figure 3. Age-specific incidence of breast ductal carcinoma in situ by age groups in Girona (Spain), 1983-2007. 
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